Bob Leibenluft's antitrust practice is unusual in that it focuses on only one industry – health care and life sciences – yet it spans all industry sectors, including providers, payers, and drug and device manufacturers. He brings over 35 years of experience, including heading the FTC Health Care Division, to his representation of clients in counseling, investigations, transactions, and litigation matters.

Starting at the firm in 1981 as a health regulatory lawyer, Bob became a nationally recognized lawyer on Medicare issues. His deep understanding of the industry was a reason he was asked to lead the FTC Health Care Division in the mid-1990s, where he supervised drafting of the FTC/DOJ Health Policy Statements, which first addressed clinical integration, and led investigations of hospital mergers and physician networks.

On a pro bono basis, Bob has led a 10-year review of the D.C. government's response to HIV/AIDs, advised the government of Liberia on a new public health law, and provided antitrust advice to the CEO Roundtable on Cancer.

Chambers USA describes Bob as "renowned for his expertise in health care antitrust and is singled out by a source as someone who really knows how the system works" and who is hailed by peers as a "terrific health care antitrust lawyer."

Bob is an inaugural fellow and former vice president of the American Health Lawyers Association. He is a former Chair of the ABA Antitrust Section's Health and Pharmaceuticals Committee, Joint Conduct Committee, and State Enforcement Committee. Bob also served as Chair of the Board of Directors of HCI3, the parent of Prometheus Payment, and Bridges-to-Excellence. He teaches the course Antitrust in the Health Care Sector at George Washington School of Law, where he is an adjunct professor.